A Case Report of Pirfenidone-Induced Lichenoid Drug Eruption in a Patient with Idiopathic Pulmonary Fibrosis.
Seung Ah YooHyo Eun ParkMiri KimHyun Jeong ParkPublished in: Annals of dermatology (2022)
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and lethal lung disease characterized by progressive dyspnea and irreversible loss of lung function. Pirfenidone is a novel anti-fibrotic and anti-inflammatory drug, which reduces deterioration in the lung function and prolongs progression-free survival in patients with IPF. However, it has adverse effects including gastrointestinal symptoms, hepatic dysfunction or skin photosensitivity, and rash. Lichenoid drug eruption (LDE) refers to lichen planus-like drug eruption usually presenting symmetric eczematous plaques with a purple hue. To date, numerous cases of LDE due to various drugs and pirfenidone-associated photosensitivity have been reported. However, a case of pirfenidone-induced LDE has been very rarely reported to our knowledge. Herein, is a case of pirfenidone-induced LDE so that clinicians can be aware of the possibility of LDE when using pirfenidone.
Keyphrases
- idiopathic pulmonary fibrosis
- lung function
- drug induced
- interstitial lung disease
- high glucose
- diabetic rats
- cystic fibrosis
- air pollution
- chronic obstructive pulmonary disease
- free survival
- multiple sclerosis
- healthcare
- anti inflammatory
- oxidative stress
- palliative care
- emergency department
- adverse drug
- endothelial cells
- case report
- electronic health record
- systemic sclerosis
- soft tissue